We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Virax Biolabs Group Ltd (VRAX) USD0.001

Sell:$1.23 Buy:$1.35 Change: $0.05 (3.91%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$1.23
Buy:$1.35
Change: $0.05 (3.91%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$1.23
Buy:$1.35
Change: $0.05 (3.91%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Contact details

Address:
Biocity Glasgow, Bo'ness Road, Newhouse
LONDON
ML1 5UH
United Kingdom
Telephone:
+44 (20) 77887414
Website:
https://www.viraxbiolabs.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VRAX
ISIN:
KYG9495L1251
Market cap:
$2.67 million
Shares in issue:
2.36 million
Sector:
Health Care Distributors
Exchange:
NASDAQ
Country:
Cayman Islands
Currency:
US dollar
Indices:
n/a

Key personnel

  • James Foster
    Chairman of the Board, Chief Executive Officer
  • Jason Davis
    Chief Financial Officer
  • Cameron Shaw
    Chief Operating Officer, Director
  • Mark Ternouth
    Chief Technical Officer
  • Tomasz George
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.